At a glance
What is it—and why does it matter?
Amycretin is a single molecule that acts as both a GLP-1 receptor agonist and an amylin receptor agonist. The study aimed to test amycretin’s safety, tolerability, pharmacokinetics, and pharmacodynamic effects in adults with overweight or obesity using single and multiple ascending doses. In this network meta-analysis, high-dose subcutaneous amycretin reduced percent body weight versus placebo by -23.95% (P score 1.00). Amycretin plasma concentrations were consistent with dose proportionality across treatment groups.
Sources for this introduction: [1] [2] [3] [4]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
Simple guide
Amycretin, in plain English
The main points from the published research. Each one links to the source it comes from.
What it is
Amycretin is a unimolecular co-agonist that targets GLP-1 and amylin receptors.
Source for this finding
“Amycretin, a novel unimolecular co-agonist targeting glucagon-like peptide-1 (GLP-1) and amylin receptors,”
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.
What the research looks like
Most published findings come from studies in people.
- 18 People 90%
- 1 Animals or lab 5%
- 1 Other or unclear 5%
Counts show where findings come from, not how strong they are. Animal and lab findings are counted together because study types have not been labelled for this profile yet.
What studies in people found
High-dose subcutaneous amycretin showed a larger percent body-weight reduction than semaglutide 2.4 mg and liraglutide 3.0 mg in this analysis.
Source for this finding
“Compared with placebo, high dose (HiD) subcutaneous amycretin produced the largest reduction in percent body weight (mean difference -23.95%; P score 1.00), followed by HiD eloralintide (-18.01%; P score 0.89) and HiD CagriSema (-17.18%; P score 0.85), all exceeding semaglutide 2.4 mg (-11.45%) and liraglutide 3.0 mg (-6.4%).”
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.People were randomly assigned to amycretin or placebo, and both participants and investigators were masked.
Source for this finding
“Participants were randomly allocated to receive amycretin or placebo, with participants and investigators masked to trial product allocation.”
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.By week 36, HbA1c fell by -1·3% with zenagamtide 25 mg; vs placebo the difference was -0·99% (95% CI -1·49 to -0·49; p=0·0001).
Source for this finding
“-1·3% with zenagamtide 25 mg (-0·99% [-1·49 to -0·49]; p=0·0001)”
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.The paper concludes high-dose amycretin may cause substantial short- to medium-term weight loss but may also increase GI side effects; the evidence is sparse and low-certainty.
Source for this finding
“Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short- to medium-term weight loss but may also increase GI AEs; given sparse, low-certainty data, these findings are preliminary and require confirmation in larger trials.”
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.By week 36, HbA1c fell by -0·9% with zenagamtide 6 mg; vs placebo the difference was -0·5% (95% CI -1·04 to -0·04; p=0·033).
Source for this finding
“At week 36, from baseline (mean range 7·9-8·1%), estimated mean change in HbA1cwas -0·9% with zenagamtide 6 mg (estimated treatment difference [ETD] vs placebo -0·5% [95% CI -1·04 to -0·04]; p=0·033)”
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
What animal and lab studies suggest
Not proven in people. Results in animals or cells often do not hold up in humans.
No main results from animal or lab studies are published here yet. 1 related finding is listed with all findings below.
Safety
No safety findings are published in this profile yet. Missing safety data does not mean it is safe.
What we don't know
- Not yet covered in this profile: administration, contraindications, interactions, regulatory status, safety.
A missing finding does not mean something is safe or effective.
See all 21 findings and sourcesEvery finding, grouped by topic, with its exact source passages
What is it?
A molecule, not a product name.
Identity
Amycretin is a unimolecular co-agonist that targets GLP-1 and amylin receptors.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Amycretin, a novel unimolecular co-agonist targeting glucagon-like peptide-1 (GLP-1) and amylin receptors,”
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives. · Abstract
Identity
Zenagamtide was formerly called amycretin.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Zenagamtide (formerly amycretin)”
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · BACKGROUND
Identity
Amycretin is mentioned as an investigational drug in a review of peptide-based amylin receptor agonists.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists (AMYRAs), including pramlintide and cagrilintide, KBP-series DACRAs, and investigational drugs, including ZP8396 and amycretin.”
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies. · Abstract
Identity
Zenagamtide was previously called amycretin.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Zenagamtide (formerly amycretin)”
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · BACKGROUND
Identity
Amycretin is a new single molecule that activates GLP-1 and amylin receptors.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist.”
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. · BACKGROUND
Identity
Amycretin is described as an emerging multiagonist therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Numerically greater placebo-subtracted reductions were seen with emerging multiagonists, including -23.9% (CI, -29.3% to -18.5%) with amycretin and -22.1% (CI, -24.9% to -19.3%) with retatrutide.”
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. · DATA SYNTHESIS
Identity
Amycretin is a single molecule that acts as both a GLP-1 receptor agonist and an amylin receptor agonist.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Amycretin is a novel, single-molecule GLP-1 receptor and amylin receptor agonist.”
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. · BACKGROUND
How does it work?
Target, response, and disposition.
Mechanism
The study aimed to test amycretin’s safety, tolerability, pharmacokinetics, and pharmacodynamic effects in adults with overweight or obesity using single and multiple ascending doses.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“We aimed to investigate the safety, tolerability, pharmacokinetic properties, and pharmacodynamic effects of single ascending doses (part A) and multiple ascending doses (parts B and C/D) of amycretin in adult participants with overweight or obesity.”
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. · BACKGROUND
Pharmacokinetics
Amycretin plasma concentrations were consistent with dose proportionality across treatment groups.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Amycretin plasma concentrations were consistent with dose proportionality across all treatment groups.”
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. · FINDINGS
Pharmacokinetics
Secondary outcomes included drug exposure (AUC) and peak plasma concentration.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Secondary endpoints were area under the plasma concentration-time curve, maximum plasma concentration, and relative change in bodyweight from baseline.”
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. · METHODS
What has been studied?
What the evidence says.
Comparative evidence
High-dose subcutaneous amycretin showed a larger percent body-weight reduction than semaglutide 2.4 mg and liraglutide 3.0 mg in this analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with placebo, high dose (HiD) subcutaneous amycretin produced the largest reduction in percent body weight (mean difference -23.95%; P score 1.00), followed by HiD eloralintide (-18.01%; P score 0.89) and HiD CagriSema (-17.18%; P score 0.85), all exceeding semaglutide 2.4 mg (-11.45%) and liraglutide 3.0 mg (-6.4%).”
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. · RESULTS
Comparative evidence
People were randomly assigned to amycretin or placebo, and both participants and investigators were masked.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Participants were randomly allocated to receive amycretin or placebo, with participants and investigators masked to trial product allocation.”
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. · METHODS
Study findings
By week 36, HbA1c fell by -1·3% with zenagamtide 25 mg; vs placebo the difference was -0·99% (95% CI -1·49 to -0·49; p=0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“-1·3% with zenagamtide 25 mg (-0·99% [-1·49 to -0·49]; p=0·0001)”
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · FINDINGS
Study findings
The paper concludes high-dose amycretin may cause substantial short- to medium-term weight loss but may also increase GI side effects; the evidence is sparse and low-certainty.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short- to medium-term weight loss but may also increase GI AEs; given sparse, low-certainty data, these findings are preliminary and require confirmation in larger trials.”
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. · CONCLUSIONS
Study findings
By week 36, HbA1c fell by -0·9% with zenagamtide 6 mg; vs placebo the difference was -0·5% (95% CI -1·04 to -0·04; p=0·033).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At week 36, from baseline (mean range 7·9-8·1%), estimated mean change in HbA1cwas -0·9% with zenagamtide 6 mg (estimated treatment difference [ETD] vs placebo -0·5% [95% CI -1·04 to -0·04]; p=0·033)”
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · FINDINGS
Study findings
By week 36, 0·4 mg zenagamtide lowered HbA1c more than placebo by -0·77%.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At week 36, estimated change in HbA1c(mean across all groups at baseline 7·8% [SD 0·8]) ranged from -0·9% with zenagamtide 0·4 mg (estimated treatment difference vs placebo: -0·77% [95% CI -1·26 to -0·28]; p=0·0021)”
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · FINDINGS
Study findings
In this network meta-analysis, high-dose subcutaneous amycretin reduced percent body weight versus placebo by -23.95% (P score 1.00).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with placebo, high dose (HiD) subcutaneous amycretin produced the largest reduction in percent body weight (mean difference -23.95%; P score 1.00)”
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. · RESULTS
Study findings
By week 36, 40 mg zenagamtide lowered HbA1c more than placebo by -1·56%.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“to -1·7% with zenagamtide 40 mg (-1·56% [-2·05 to -1·07]; p<0·0001).”
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · FINDINGS
Study findings
Amycretin is reported to have -23.9% placebo-subtracted weight loss (CI, -29.3% to -18.5%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Numerically greater placebo-subtracted reductions were seen with emerging multiagonists, including -23.9% (CI, -29.3% to -18.5%) with amycretin and -22.1% (CI, -24.9% to -19.3%) with retatrutide.”
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. · DATA SYNTHESIS
Study findings
By week 36, HbA1c fell by -1·4% with zenagamtide 50 mg; vs placebo the difference was -1·09% (95% CI -1·59 to -0·59; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“-1·4% with zenagamtide 50 mg (-1·09% [-1·59 to -0·59]; p<0·0001)”
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · FINDINGS
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Additional research & classification gaps
1 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (1)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Amycretin is an amylin-based agent.
Research context only—not evidence of a treatment effect.
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions.
Research status + gaps
What still needs better answers?
- Not yet covered in this profile: administration, contraindications, interactions, regulatory status, safety.
- Some extracted findings are not shown because they did not pass Peplexicon's automated evidence checks.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. ↗
pubmed · published July 12, 2025 · retrieved September 4, 2026
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. ↗
pubmed · published July 12, 2025 · retrieved September 9, 2026
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. ↗
pubmed · published March 11, 2026 · retrieved August 25, 2026
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies. ↗
pubmed · published March 1, 2026 · retrieved September 2, 2026
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives. ↗
pubmed · published June 1, 2026 · retrieved August 25, 2026
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. ↗
pubmed · published May 1, 2026 · retrieved August 25, 2026
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗
pubmed · published August 15, 2026 · retrieved August 25, 2026
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗
pubmed · published August 15, 2026 · retrieved August 25, 2026
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. ↗
pubmed · published September 1, 2026 · retrieved September 1, 2026
Publication history and provenance
Version 3 · Automated assessment · September 9, 2026
8e67de14456559581350a4688b00277989ec6d03b43384831227f1038382bdda